Chronic Disease Management Stocks
Specialized healthcare providers and biopharmaceutical developers in this sector target high-cost, recurring patient needs through clinical interventions, medical devices, and integrated insurance management.
As of Oct 23, 2026, Chronic Disease Management has 27 US-listed companies worth $98.3B combined. The median member moved +4.2% over the past week; HNGE led among the 25 largest at +12.5% and EYPT trailed at -86.5%.
Companies in Chronic Disease Management
- RMD – ResMed Inc, $35.6B
- DVA – DaVita HealthCare Partners Inc, $11.9B
- FMS – Fresenius Medical Care Corporation, $11.8B
- PODD – Insulet Corporation, $10.3B
- HNGE – Hinge Health, Inc., $8.9B
- IMVT – Immunovant Inc, $5.9B
- OPCH – Option Care Health Inc, $4.7B
- ALHC – Alignment Healthcare LLC, $1.7B
- AGL – agilon health Inc, $1.4B
- OMDA – Omada Health, Inc. Common Stock, $1.1B
- TDOC – Teladoc Inc, $1B
- PIII – P3 Health Partners Inc, $821M
- AHCO – Adapthealth Corp, $770M
- PROK – ProKidney Corp., $695M
- TCMD – Tactile Systems Technology Inc, $501M
- EMBC – Embecta Corp, $389M
- VMD – Viemed Healthcare Inc, $355M
- AKBA – Akebia Ther, $171M
- KRMD – Repro Med Systems Inc, $136M
- DRIO – DarioHealth Corp, $56.8M
- IXHL – Incannex Healthcare Inc., $40.3M
- EYPT – EyePoint, Inc, $34M
- UPC – Universe Pharmaceuticals Inc, $20.9M
- ACH – Accendra Health Inc, $19.6M
- MODD – Modular Medical Inc, $15.9M
- POM – POMDOCTOR LIMITED American Depositary Shares, $6.9M
- VAXX – Vaxxinity Inc, $12,678